CN104547757A - 一种治疗扁桃体炎、腺样体肥大的中药 - Google Patents
一种治疗扁桃体炎、腺样体肥大的中药 Download PDFInfo
- Publication number
- CN104547757A CN104547757A CN201510041485.3A CN201510041485A CN104547757A CN 104547757 A CN104547757 A CN 104547757A CN 201510041485 A CN201510041485 A CN 201510041485A CN 104547757 A CN104547757 A CN 104547757A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- grams
- treatment
- traditional chinese
- amygdalitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 39
- 206010001229 Adenoidal hypertrophy Diseases 0.000 title claims abstract description 37
- 201000003462 adenoid hypertrophy Diseases 0.000 title abstract 4
- 210000000582 semen Anatomy 0.000 claims abstract description 27
- 210000003038 endothelium Anatomy 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 11
- 206010044008 tonsillitis Diseases 0.000 claims description 30
- 241000628997 Flos Species 0.000 claims description 13
- 241000283956 Manis Species 0.000 claims description 13
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 13
- 206010011224 Cough Diseases 0.000 abstract description 15
- 210000004072 lung Anatomy 0.000 abstract description 10
- 230000008961 swelling Effects 0.000 abstract description 8
- 208000002193 Pain Diseases 0.000 abstract description 6
- 230000036407 pain Effects 0.000 abstract description 6
- 206010003694 Atrophy Diseases 0.000 abstract description 5
- 230000037444 atrophy Effects 0.000 abstract description 5
- 210000004907 gland Anatomy 0.000 abstract description 4
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 241000935235 Fritillaria meleagris Species 0.000 abstract 1
- 241000283966 Pholidota <mammal> Species 0.000 abstract 1
- 244000018633 Prunus armeniaca Species 0.000 abstract 1
- 235000009827 Prunus armeniaca Nutrition 0.000 abstract 1
- 244000050591 Veronicastrum sibiricum Species 0.000 abstract 1
- 235000000756 Veronicastrum sibiricum Nutrition 0.000 abstract 1
- 244000137773 Viola philippica Species 0.000 abstract 1
- 229910052602 gypsum Inorganic materials 0.000 abstract 1
- 239000010440 gypsum Substances 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 17
- 208000024891 symptom Diseases 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 210000002741 palatine tonsil Anatomy 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 231100000614 poison Toxicity 0.000 description 9
- 208000006673 asthma Diseases 0.000 description 8
- 239000003440 toxic substance Substances 0.000 description 8
- 208000033809 Suppuration Diseases 0.000 description 7
- 210000000265 leukocyte Anatomy 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 208000001705 Mouth breathing Diseases 0.000 description 6
- 210000003800 pharynx Anatomy 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 210000000253 proventriculus Anatomy 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 206010007247 Carbuncle Diseases 0.000 description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000003448 neutrophilic effect Effects 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical group CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 4
- 206010020565 Hyperaemia Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 238000009534 blood test Methods 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 208000019505 Deglutition disease Diseases 0.000 description 3
- 206010068319 Oropharyngeal pain Diseases 0.000 description 3
- 201000007100 Pharyngitis Diseases 0.000 description 3
- 208000025747 Rheumatic disease Diseases 0.000 description 3
- 206010041235 Snoring Diseases 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 201000007227 lymph node tuberculosis Diseases 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000000552 rheumatic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 206010003011 Appendicitis Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 206010019345 Heat stroke Diseases 0.000 description 2
- 206010028748 Nasal obstruction Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- IUKLSMSEHKDIIP-BZMYINFQSA-N Verticine Chemical compound C([C@@H]1[C@@H](O)C[C@H]2[C@@H]3CC[C@@H]4[C@]5(C)O)[C@@H](O)CC[C@]1(C)[C@H]2C[C@H]3[C@@H]4CN1[C@H]5CC[C@H](C)C1 IUKLSMSEHKDIIP-BZMYINFQSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 210000002534 adenoid Anatomy 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 208000002399 aphthous stomatitis Diseases 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 229940126678 chinese medicines Drugs 0.000 description 2
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 208000027043 ear symptom Diseases 0.000 description 2
- 229960002179 ephedrine Drugs 0.000 description 2
- 210000003026 hypopharynx Anatomy 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 206010024378 leukocytosis Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 201000003453 lung abscess Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- IUKLSMSEHKDIIP-UHFFFAOYSA-N petine Natural products CC1(O)C2CCC3C4CC(O)C5CC(O)CCC5(C)C4CC3C2CN2C1CCC(C)C2 IUKLSMSEHKDIIP-UHFFFAOYSA-N 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- XUCIJNAGGSZNQT-JHSLDZJXSA-N (R)-amygdalin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H](C#N)C=2C=CC=CC=2)O1 XUCIJNAGGSZNQT-JHSLDZJXSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 241000321096 Adenoides Species 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010009152 Chronic tonsillitis Diseases 0.000 description 1
- 235000007354 Coix lacryma jobi Nutrition 0.000 description 1
- 244000077995 Coix lacryma jobi Species 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020046 High arched palate Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- 206010034107 Pasteurella infections Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010072610 Skeletal dysplasia Diseases 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 208000009911 Urinary Calculi Diseases 0.000 description 1
- 241000934136 Verruca Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 230000037006 agalactosis Effects 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 210000004727 amygdala Anatomy 0.000 description 1
- 229940089837 amygdalin Drugs 0.000 description 1
- YZLOSXFCSIDECK-UHFFFAOYSA-N amygdalin Natural products OCC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC(C#N)c3ccccc3 YZLOSXFCSIDECK-UHFFFAOYSA-N 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000014461 bone development Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 201000001747 discharging ear Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- YGHHWSRCTPQFFC-UHFFFAOYSA-N eucalyptosin A Natural products OC1C(O)C(O)C(CO)OC1OC1C(OC(C#N)C=2C=CC=CC=2)OC(CO)C(O)C1O YGHHWSRCTPQFFC-UHFFFAOYSA-N 0.000 description 1
- 210000002388 eustachian tube Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000008921 facial expression Effects 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 210000001983 hard palate Anatomy 0.000 description 1
- 201000000615 hard palate cancer Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- -1 luteolin glycosides Chemical class 0.000 description 1
- 230000032630 lymph circulation Effects 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 208000005923 otitis media with effusion Diseases 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 201000005115 pasteurellosis Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 208000024036 serous otitis media Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 208000026473 slurred speech Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/86—Violaceae (Violet family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8966—Fritillaria, e.g. checker lily or mission bells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明属于中药领域,特别公开了一种治疗扁桃体炎、腺样体肥大的中药。该中药以金银花、紫花地丁、生石膏、薏苡仁、草威灵仙、浙贝母、炒鸡内金、穿山甲、杏仁和蜜麻黄为活性成分,按一定的重量份数组成。发明的中药专门用于治疗扁桃体炎、腺样体肥大,具有消肿止痛、清热解毒,宣肺、止咳,散结、促进肥大腺体萎缩的功效。解决了现有药物治疗扁桃体炎起效慢、疗程长容易反复的问题,同时能够促进肥大腺体萎缩,避免了扁桃体、腺样体肥大需手术切除的痛苦,总有效率达96%。
Description
(一)技术领域
本发明属于中药领域,特别涉及一种治疗扁桃体炎、腺样体肥大的中药。
(二)背景技术
扁桃体炎是一种临床常见病、多发病,为扁桃体慢性感染所引起的弥漫性咽部病变,患者常出现咽喉肿痛、吞咽困难等症状,该病易反复发作,导致扁桃体的免疫功能受到影响,使人体的抗病力减弱。腺样体位于鼻咽部顶部与咽后壁处,构成咽淋巴循环的重要组成部分,当腺样体因炎症如鼻炎、扁桃体炎反复发作发生病理性增生导致腺样体肥大时,患者会出现鼻塞、打鼾、张口呼吸等临床症状,严重者可引起呼吸暂停,影响大脑供氧。此外,腺样体肥大导致咽鼓管口堵塞后会引起分泌性中耳炎,炎症分泌物下流会刺激咽喉及器官,引起咳嗽吐痰、气喘等,患者由于长期张口呼吸,还会影响面骨发育而致上颔骨狭长、硬腭高拱变窄、牙齿咬合不良、面部表情呆滞,呈现腺样体面容。小儿腺样体肥大是儿科较为常见的疾病,多病发于十岁以下的小儿,病情反复,迁延难愈,容易导致多种并发症,严重影响小儿的身心健康和生长发育。
目前对于治疗扁桃体炎、腺样体肥大采用的普遍药物治疗方法是使用抗生素类药物,虽然起效较快,对症状有所缓解,但是治标不治本,时而有效,时而反复,不能彻底治愈,容易反复发作。并且,长期采用抗生素治疗会破坏、削弱人体淋巴组织的免疫功能,长久下去对人体危害很大。患病严重时,患者不得不采用手术切除扁桃体或者腺样体增生组织,病人痛苦大,医疗费用高。虽然市面上也出现了一些用于治疗扁桃体炎、腺样体肥大的中药,但这些中药大多以消炎、消肿、清热解毒为主,只能减轻患者的炎症,而对炎症长期反复发作导致的扁桃体、腺样体肥大问题,疗效较差。
(三)发明内容
本发明为了弥补现有技术的不足,提供了一种制备简单、服用方便、有效缓解扁桃体炎、促进肥大腺样体萎缩、治愈率高、疗效显著持久的治疗扁桃体炎、腺样体肥大的中药。
本发明是通过如下技术方案实现的:
一种治疗扁桃体炎、腺样体肥大的中药,其活性成分由以下重量份数的原料组成:
金银花3-5份、紫花地丁3-5份、生石膏1.5-3份、薏苡仁3-5份、草本威灵仙0.5-1份、浙贝母1.5-3份、炒鸡内金1.5-3份、穿山甲0.5-1份、杏仁0.5-1份和蜜麻黄0.5-1份。
其优选的各活性成分的重量配比为:
金银花4份、紫花地丁4份、生石膏2.25份、薏苡仁4份、草本威灵仙0.75份、浙贝母2.25份、炒鸡内金2.25份、穿山甲0.75份、杏仁0.75份和蜜麻黄0.75份。
制备方法:称取将上述重量分数的各原料,粉碎成150-200目细粉后混合,即得该治疗扁桃体炎、腺样体肥大的中药。
用法用量:每日服用5-10g,分早、晚两次开水冲服,一个月为一疗程,一般2-3个疗程即可痊愈。
本发明所采用的各活性成分的药用性能如下所示:
金银花:味甘、性寒,归肺、胃经。具有清热解毒之功。主治外感风热或温病发热,中暑,热毒血痢,痈肿疔疮,喉痹,多种感染性疾病。现代医学研究表明,金银花含有绿原酸、木犀草素苷等药理活性成分,具有抗菌抗病毒、抗细菌病毒、解热抗炎、凉血止血等作用;
紫花地丁:味苦、辛,性寒,归心、肝经。具有清热解毒、燥湿凉血之功。主治疔疮痈疽,丹毒,痄腮,乳痈,肠痈,瘰疬,湿热泻痢,黄疸,目赤肿痛,蛇毒咬伤。现代医学研究表明,紫花地丁所含黄酮甙类及有机酸对金色葡萄球菌、猪巴氏杆菌、大肠杆菌、链球菌和沙门氏菌都有较强的抑菌作用;
生石膏:味辛、甘,性寒,归胃、肺经。具有清热泻火、除烦止渴之功。主治热病高热,烦渴,神昏谵语,发狂,肺热喘咳,中暑,胃火头痛、牙痛,口舌生疮。现代医学研究表明:生石膏内服经胃酸作用,一部分变成可溶性钙盐,至肠吸收入血后能增加血清内钙离子的浓度,可抑制体温调节中枢、减轻骨骼肌的兴奋性、减少血管通透性,有解热、镇痉、消炎等作用;
薏苡仁:味甘、淡,性微寒,归脾、胃、肺经。具有利湿健脾,舒筋除痹,清热排脓之功。主治水肿,脚气,小便淋沥,湿温病,泄泻,带下,风湿麻痹,筋脉拘挛,肺痈,肠痈,扁平疣。现代医学研究表明,薏苡仁所含薏苡内酯具有镇静、镇痛、抗菌等作用;
草本威灵仙:味辛、微苦,性寒,具有祛风除湿,清热解毒之功。主治感冒风热,咽喉肿痛,腮腺炎,风湿痹痛,虫蛇所伤。现代医学研究表明:草本威灵仙的纯提取物具有显著的抗炎镇痛作用;
浙贝母:味苦、性寒,归肺,心经。具有清热化痰,降气止咳,散结消肿之功。主治风热或痰热咳嗽,肺痈吐脓,瘰疬瘿瘤,疮痈肿毒。现代医学研究表明:浙贝母中所含浙贝母碱对金黄色葡萄球菌及大肠埃希菌都有明显抑菌作用,此外,浙贝母碱还具有镇咳平喘的作用;
炒鸡内金:味甘、涩,性平,归脾、胃、膀胱经。具有健脾胃,消食积,化石之功。主治食积,泄泻,小儿疳积,胆石症,石淋,砂淋,癓瘕经闭,喉痹乳蛾,牙疳口疮;
穿山甲:味咸,性微苦,归肝、胃经。具有活血通经,下乳,消痈之功。主治血瘀经闭,癓瘕,风湿痹痛,乳汁不下,臃肿,瘰疬。现代医学研究表明:穿山甲的提取物具有抗炎杀菌作用;
杏仁:味苦,性微温,归肺、大肠经。具有降气化痰,止咳平喘,润肠通便之功。主治外感咳嗽喘满,肠燥便秘。现代医学研究表明:杏仁中含有的苦杏仁甙成分不仅能止咳平喘,还具有抗击肿瘤的作用;
蜜麻黄:味辛、微苦,性温,归肺、膀胱经。具有发汗解表,宜肺平喘,利水消肿之功。主治风寒表实证,咳嗽气喘,风水,小便不利,风湿痹痛,肌肤不仁,风疹瘙痒,阴疽痰核。现代医学研究表明:麻黄所含主要成分是麻黄碱,麻黄碱能够收缩平滑肌,起到止咳平喘的作用。
本发明中药各原料合理搭配,科学组方,所含金银花清解血毒、疏散风热,紫花地丁清热解毒、燥湿凉血,生石膏清热泻火、除烦止渴,薏苡仁利湿健脾、清热排脓,草本威灵仙祛风除湿、清热解毒,浙贝母清热化痰、降气止咳、散结消肿,鸡内金软坚消积、活血化瘀,穿山甲活血消痈、解毒软坚,杏仁降气化痰、止咳平喘,蜜麻黄宜肺平喘、利水消肿。
本发明的中药专门用于治疗扁桃体炎、腺样体肥大,金银花、紫花地丁、生石膏、薏苡仁、草本威灵仙、浙贝母具有消肿止痛、清热解毒的功效,炒鸡内金、穿山甲具有散结、促进肥大腺体萎缩的功效,杏仁、蜜麻黄具有宣肺、止咳的功效;将多种药物合理搭配,利用其相互间的协同或抵抗作用,提高疗效,以适应复杂病情的治疗要求,解决了现有药物治疗扁桃体炎起效慢、疗程长、容易反复的问题,同时能够促进肥大腺体萎缩,避免了扁桃体、腺样体肥大需手术切除的痛苦,减少不良反应,疗效显著持久,吸收快,奏效迅速,作用强,无刺激性,安全可靠,制备简单,服用方便,药源充足,价格适宜。经过多年临床应用验证,能够有效治疗扁桃体炎、腺样体肥大,总有效率达96%。
(四)具体实施方式
实施例1:
称取金银花40克、紫花地丁40克、生石膏22.5克、薏苡仁40克、草本威灵仙7.5克、浙贝母22.5克、炒鸡内金22.5克、穿山甲7.5克、杏仁7.5克和蜜麻黄7.5克,将上述各原料粉碎成150-200目细粉后混合,即得该治疗扁桃体炎、腺样体肥大的中药。
用法用量:每日服用5-10g,分早、晚两次开水冲服,一个月为一疗程,一般2-3个疗程即可痊愈。
实施例2:
该治疗扁桃体炎、腺样体肥大的中药,其活性成分由以下重量的原料组成:
金银花30克、紫花地丁30克、生石膏15克、薏苡仁30克、草本威灵仙5克、浙贝母15克、炒鸡内金15克、穿山甲5克、杏仁5克和蜜麻黄5克。
制备方法与用法用量同实施例1。
实施例3:
该治疗扁桃体炎、腺样体肥大的中药,其活性成分由以下重量的原料组成:
金银花50克、紫花地丁50克、生石膏30克、薏苡仁50克、草本威灵仙10克、浙贝母30克、炒鸡内金30克、穿山甲10克、杏仁10克和蜜麻黄10克。
制备方法与用法用量同实施例1。
实施例4:
该治疗扁桃体炎、腺样体肥大的中药,其活性成分由以下重量的原料组成:
金银花35克、紫花地丁35克、生石膏18.5克、薏苡仁35克、草本威灵仙6.3克、浙贝母18.5克、炒鸡内金18.5克、穿山甲6.3克、杏仁6.2克和蜜麻黄6.2克。
制备方法与用法用量同实施例1。
实施例5:
该治疗扁桃体炎、腺样体肥大的中药,其活性成分由以下重量的原料组成:
金银花45克、紫花地丁45克、生石膏26克、薏苡仁45克、草本威灵仙8.8克、浙贝母26克、炒鸡内金26克、穿山甲8.8克、杏仁8.8克和蜜麻黄8.8克。
制备方法与用法用量同实施例1。
临床观察:
(1)临床资料
为了验证本中药的疗效,本发明人先后对门诊就诊的230例扁桃体炎患者、230例腺样体肥大的患者进行临床验证。
230例扁桃体炎患者中,女103例,男127例,年龄5-40岁,平均年龄26.7岁,病程1个月-3年,诊断后分为治疗组A 115例和对照组A 115例,两组患者的性别组成、年龄、病程无明显差异。
230例腺样体肥大患者中,女122例,男108例,年龄5-12岁,平均年龄7.3岁,病程6个月-2年,诊断后分为治疗组B 115例和对照组B 115例,两组患者的性别组成、年龄、病程无明显差异。
(2)诊断标准
扁桃体炎:咽部检查见扁桃体充血、肿大、表面有黄白色脓性分泌物,血常规检查白细胞、中性粒细胞增多,多伴有发热、恶寒、头晕等症状。
腺样体肥大:X射线侧位拍片检查可见肥大的腺样体,具体症状为:
a.鼻部症状:鼻堵,张口呼吸,睡眠时有鼾声,语言不清,带鼻音,鼻腔分泌物增多;
b.耳部症状:因咽鼓管被堵塞,引起耳部症状,可有耳鸣,耳流脓;
c.咽喉及下呼吸道症状:因鼻腔分泌物倒流,刺激咽喉部引起咳嗽,咽喉不适,常有上呼吸道感染和病发支气管炎;
d.上颔面部骨骼发育不良:由于长期张口呼吸,使上颔骨狭窄增长,硬腭狭窄,高拱,牙齿排列不齐,上唇后短,缺乏表情,张口呆傻。
(2)治疗方法
治疗组服用本发明所制中药,每日服用5-10g,分早、晚两次开水冲服,一个月为一疗程,服用2-3个疗程,对照组服用阿莫西林治疗。
(3)疗效判定标准
“治愈”:扁桃体无充血和脓点,肿大消失,腺样体肥大症状消失,血常规化验白细胞、中性粒细胞正常。
“显效”:扁桃体充血明显减轻,脓点消除,肿大减轻,腺样体肥大症状明显减轻,血常规化验趋于正常。
“有效”:扁桃体充血和脓点减轻,腺样体肥大症状减轻,扁桃体偶尔出现肿痛,血常规化验白血球稍高于正常值。
“无效”:扁桃体充血和脓点、肿大无明显变化,腺样体肥大症状无改善,血常规化验白血球高于正常值。
(5)治疗效果:见下表1
表1试验组和对照组治疗扁桃体炎、腺样体肥大的临床效果
组别 | 例数 | 治愈 | 显效 | 有效 | 无效 | 总有效率 |
治疗组A | 115 | 71 | 29 | 11 | 4 | 96.5% |
对照组A | 115 | 41 | 34 | 21 | 19 | 83.5% |
治疗组B | 115 | 58 | 42 | 10 | 5 | 95.6% |
对照组B | 115 | 9 | 17 | 11 | 78 | 32.2% |
从表1中数据可以看到,本发明的中药治疗扁桃体炎、腺样体肥大的疗效显著。
(6)副作用及禁忌症
经过460例患者的临床应用,观察未发现明显毒副作用。孕妇及哺乳期妇女忌用。
典型病例:
病例1:张某,男,7岁,自小体弱多病,就诊时咽部检查见双侧扁桃体肿大化脓,X射线侧位拍片检查可见肥大的腺样体,平时吞咽困难,需用口呼吸,血常规检查白细胞、中性粒细胞增多,在医院确诊为扁桃体炎、腺样体肥大,屡治无效后服用本发明实施例1所制中药,每日服用5-10g,分早、晚两次开水冲服,一个月为一疗程,一个疗程后扁桃体炎症状消失,血常规检查白细胞、中性粒细胞正常,两个疗程后腺样体肥大减轻,三个疗程后治愈,至今未复发。
病例2:李某,女,23岁,反复发作性扁桃体炎3年,每因外感风寒即复发,吞咽困难,伴有发热、头晕等症状,患者不愿反复使用抗生素治疗,要求口服中药治疗,服用本发明实施例2所制中药,每日服用5-10g,分早、晚两次开水冲服,一个月为一疗程,两个疗程治愈,血常规检查白细胞、中性粒细胞正常,观察一年未复发。
病例3:韩某,男,15岁,自诉患慢性扁桃体炎两年多,常年干咳不止,吞咽食物时咽喉疼痛,咽部检查见扁桃体充血、肿大、表面有黄白色脓性分泌物。服用本发明实施例3所制中药,每日服用5-10g,分早、晚两次开水冲服,一个月为一疗程,一个疗程症状减轻,继续服用,两个疗程治愈,观察一年未复发。
病例4:兰某,女,8岁,就诊时X射线侧位拍片检查可见肥大的腺样体,讲话语言不清,带鼻音,鼻腔分泌物增多,据其父母讲述,睡眠时有鼾声,由于长期张口呼吸,使上颔骨狭窄增长,缺乏表情。服用本发明实施例5所制中药,每日服用5-10g,分早、晚两次开水冲服,一个月为一疗程,一个疗程腺样体肥大症状减轻,三个疗程治愈,至今未复发。
Claims (2)
1.一种治疗扁桃体炎、腺样体肥大的中药,其特征是:其活性成分由以下重量份数的原料组成:金银花3-5份、紫花地丁3-5份、生石膏1.5-3份、薏苡仁3-5份、草本威灵仙0.5-1份、浙贝母1.5-3份、炒鸡内金1.5-3份、穿山甲0.5-1份、杏仁0.5-1份和蜜麻黄0.5-1份。
2.根据权利要求1所述的治疗扁桃体炎、腺样体肥大的中药,其特征是:其活性成分由以下重量份数的原料组成:金银花4份、紫花地丁4份、生石膏2.25份、薏苡仁4份、草本威灵仙0.75份、浙贝母2.25份、炒鸡内金2.25份、穿山甲0.75份、杏仁0.75份和蜜麻黄0.75份。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510041485.3A CN104547757B (zh) | 2015-01-27 | 2015-01-27 | 一种治疗扁桃体炎、腺样体肥大的中药 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510041485.3A CN104547757B (zh) | 2015-01-27 | 2015-01-27 | 一种治疗扁桃体炎、腺样体肥大的中药 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104547757A true CN104547757A (zh) | 2015-04-29 |
CN104547757B CN104547757B (zh) | 2018-03-23 |
Family
ID=53065528
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510041485.3A Expired - Fee Related CN104547757B (zh) | 2015-01-27 | 2015-01-27 | 一种治疗扁桃体炎、腺样体肥大的中药 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104547757B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110420298A (zh) * | 2019-09-04 | 2019-11-08 | 山东大学齐鲁医院 | 一种治疗鼻甲肥大、鼻息肉的中药组合物 |
JP2022532003A (ja) * | 2019-05-08 | 2022-07-13 | ケーティー アンド ジー コーポレイション | クガイソウ抽出物を有効成分として含む炎症、アレルギー及び喘息の予防用または治療用の組成物、及びその用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1911408A (zh) * | 2006-08-15 | 2007-02-14 | 黄南锡 | 一种治疗肺胃热盛型急性扁桃体炎的汤剂药物及制备方法 |
CN1965960A (zh) * | 2006-08-10 | 2007-05-23 | 黄志良 | 一种治疗急性扁桃体炎的汤剂药物及制备方法 |
-
2015
- 2015-01-27 CN CN201510041485.3A patent/CN104547757B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1965960A (zh) * | 2006-08-10 | 2007-05-23 | 黄志良 | 一种治疗急性扁桃体炎的汤剂药物及制备方法 |
CN1911408A (zh) * | 2006-08-15 | 2007-02-14 | 黄南锡 | 一种治疗肺胃热盛型急性扁桃体炎的汤剂药物及制备方法 |
Non-Patent Citations (3)
Title |
---|
屈宏宇: "中医清上通下法配合抗感染治疗慢性扁桃体炎临床观察", 《辽宁中医药大学学报》 * |
蒋锴等: "中医药治疗小儿腺样体肥大", 《长春中医药大学学报》 * |
谭慧珍: "中医中药治疗急性扁桃体炎44例临床小结", 《中级医刊》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022532003A (ja) * | 2019-05-08 | 2022-07-13 | ケーティー アンド ジー コーポレイション | クガイソウ抽出物を有効成分として含む炎症、アレルギー及び喘息の予防用または治療用の組成物、及びその用途 |
JP7276995B2 (ja) | 2019-05-08 | 2023-05-18 | ケーティー アンド ジー コーポレイション | クガイソウ抽出物を有効成分として含む炎症、アレルギー及び喘息の予防用または治療用の組成物、及びその用途 |
CN110420298A (zh) * | 2019-09-04 | 2019-11-08 | 山东大学齐鲁医院 | 一种治疗鼻甲肥大、鼻息肉的中药组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN104547757B (zh) | 2018-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102949553B (zh) | 一种治疗浅表性胃炎的中药组合物 | |
CN102688384B (zh) | 一种治疗慢性咽炎的中药汤剂 | |
CN104547757B (zh) | 一种治疗扁桃体炎、腺样体肥大的中药 | |
CN106038965A (zh) | 一种治疗喉咙病症的中药组合物 | |
CN104491825B (zh) | 一种治疗口腔溃疡的中药药膏 | |
CN104352856B (zh) | 一种治疗复发性口腔溃疡的中药组合物 | |
CN105362579A (zh) | 治疗感冒的中药制剂及制备方法 | |
CN105125789A (zh) | 治疗胃痛的健脾和胃制剂及制备方法 | |
CN104225569A (zh) | 一种治疗慢性肠炎的中药组合物 | |
CN105267678B (zh) | 用于颌骨骨髓炎的中药组合物 | |
CN104606533A (zh) | 一种治疗咽炎的中药汤剂 | |
CN104127691A (zh) | 治疗口腔溃疡的含漱液 | |
CN102641442B (zh) | 一种治疗复发性口疮的中药制剂 | |
CN103372185B (zh) | 治疗慢性支气管炎的药物 | |
CN105561213A (zh) | 一种用于急性痛风性关节炎的外敷中药 | |
CN104474286A (zh) | 一种治疗燥热伤肺型慢性支气管炎的中药组合物 | |
CN104689238A (zh) | 一种结肠炎灌肠剂 | |
CN104998189A (zh) | 一种治疗风热乘脾型小儿口疮的中药散剂及其制备方法 | |
CN104491537A (zh) | 一种治疗风湿性心脏病的中药组合物 | |
CN104491391A (zh) | 一种治疗咽炎的中药组合物 | |
CN104800580A (zh) | 治疗扁桃体炎的中药方剂 | |
CN105106444B (zh) | 一种治疗流行性腮腺炎的组合物及制备方法 | |
CN104547279A (zh) | 一种治疗热毒气滞型急性扁桃体炎的中药 | |
CN107715098A (zh) | 一种和胃散寒、清泄胆热制剂 | |
CN104258361A (zh) | 一种治疗小儿哮喘的中药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20180208 Address after: 250012 Shandong, Lixia District, Ji'nan Province Cultural Road West, No. 107 Applicant after: Shandong Qilu Hospital Address before: 250012 Qilu Hospital, Shandong University, Lixia West Road, Lixia District, Shandong, Ji'nan 107, China Applicant before: Jiang Hua |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180323 Termination date: 20190127 |